1. Overnight Night Market Trends - INTERNATIONAL PRECIOUS METALS: COMEX gold futures fell 0.45% to $4126.90 per ounce, down 2.05% for the week; COMEX silver futures dropped 0.60% to $48.41 per ounce, down 3.38% for the week [4] - CRUDE OIL: The U.S. oil main contract fell 0.57% to $61.44 per barrel, up 7.51% for the week; Brent crude's main contract declined 0.57% to $64.92 per barrel, up 7.06% for the week [5] - LONDON BASE METALS: LME copper rose 0.85% to $10947 per ton, up 3.23% for the week; LME lead increased 0.30% to $2016.50 per ton, up 2.36% for the week; LME zinc edged up 0.07% to $3019.50 per ton, up 2.93% for the week; LME aluminum dropped 0.21% to $2856.50 per ton, up 2.84% for the week; LME nickel fell 0.25% to $15325 per ton, up 1.32% for the week; LME tin declined 0.34% to $35650 per ton, up 1.75% for the week [5] - DOMESTIC FUTURES: As of the close on October 24 at 23:00, domestic futures' main contracts mostly rose. Low - sulfur fuel oil, LPG, and fuel oil rose over 1%, while asphalt, coking coal, and rapeseed meal had small increases. Synthetic rubber, caustic soda, corn, and sugar slightly declined [5] 2. Important Information Macroeconomic Information - President Xi Jinping will visit South Korea from October 30 to November 1 to attend the 32nd APEC Economic Leaders' Meeting and conduct a state visit [8] - The "Proposal of the Central Committee of the Communist Party of China for Formulating the 15th Five - Year Plan for National Economic and Social Development" aims to break market barriers [8] - The central bank will conduct 900 billion yuan of MLF operations on October 27 [8] - The China Securities Regulatory Commission emphasizes enhancing the resilience and risk - resistance of the capital market [8] - Shipping indices show an increase in export container freight rates [9] - The central bank will adjust monetary policy according to economic and financial conditions and maintain the stability of the RMB exchange rate [9][10] - U.S. September CPI is slightly lower than expected, paving the way for a rate cut [10] - U.S. October PMI data shows improvement [10] - China and the U.S. held economic and trade consultations in Kuala Lumpur, reaching preliminary consensus on multiple issues [10][11] Energy and Chemical Futures - Russia's central bank forecasts average oil prices for 2025 and 2026 [12] - India's Reliance Industries bought hundreds of thousands of barrels of crude oil due to concerns about supply disruptions [14] Metal Futures - China's non - ferrous metal industry had a good performance in the first three quarters [16] - Last week, copper, aluminum, zinc, and lead inventories decreased, while nickel and tin inventories increased [17] - This month's estimated retail sales of narrow - sense passenger cars are about 2.2 million, with a decline in both month - on - month and year - on - year terms, and the penetration rate of new energy vehicles may reach 60% [17] Black - Series Futures - In mid - October, steel production of key enterprises had different trends in daily output [19] - The Ministry of Industry and Information Technology solicits opinions on the "Implementation Measures for Capacity Replacement in the Iron and Steel Industry", with specific replacement ratios and restrictions [19][21] - Some steel mills in Tangshan and Xingtai plan to raise coke prices [21] - This week's total urban inventory of steel decreased [22] - Shanxi is increasing coal production to meet winter demand, with a 3.7% year - on - year increase in the first three quarters [22] Agricultural Futures - Pig - farming losses have decreased [24] - Pig and pork prices are expected to stop falling and rise slightly in the second half of the fourth quarter [25] - In the 43rd week, soybean crushing volume in oil mills exceeded expectations [25] - Imported cotton port inventory increased slightly [26] - The domestic edible vegetable oil market is expected to have stable prices, while palm oil prices may rise slightly [28] - Malaysia's October 1 - 25 palm oil exports are expected to decline 0.4% [29] 3. Financial Markets Finance - Many A - share companies released positive third - quarter reports, with some having significant profit growth [31] - Fund managers will adjust investment strategies based on third - quarter reports, focusing on technology stocks [31] - As of the end of the third quarter, social security funds held shares in 135 stocks, with new entries, increases, and decreases in positions, and increased investment in technology sectors [32] - Many A - share companies were surveyed by institutions, with technology stocks being popular [34] - Many companies distributed dividends, and some will distribute more in the future [34] - Nearly 2000 public funds' third - quarter reports show that innovation - related assets are the main allocation [34] - The market sentiment has stabilized, and the subsequent adjustment space may be limited [34] - Hong Kong stocks' "B - series" varieties are being sold by pharmaceutical fund managers, and innovation - drug funds are entering the stock - selection stage [35] Industry - A draft regulatory guideline for public fund performance comparison benchmarks may be released soon, and many funds have adjusted their benchmarks this year [36] - Banks have raised the minimum investment threshold for gold accumulation, and short - term gold price fluctuations may be normal [38] - Gold jewelry brands have raised prices, mainly to increase processing fees and maintain stable margins [38] - Many real - estate companies have made breakthroughs in debt restructuring [38] - As of September, China's power generation installed capacity increased, with significant growth in solar and wind power [39] - The flu vaccine vaccination season has arrived, with different price trends for different vaccines [39] - Multiple paper companies will raise the price of white cardboard from November 1 [39] Overseas - The U.S. and Vietnam, Thailand, Malaysia, and Cambodia reached trade - related agreements [41][42] - The U.S. Treasury Secretary believes inflation will continue to decline, and the government shutdown is eroding the economy [42] - The U.S. government shutdown may last until the end of November [43] - The IMF President suggests that ASEAN economies strengthen their fundamentals and predicts that AI will affect a large proportion of jobs [43] International Stock Markets - European countries will implement winter time starting Monday, adjusting trading and data - release times [45] Bonds - As of October 24, the issuance scale of securities firms' science and technology innovation bonds this year reached 59.17 billion yuan, and it is expected to continue growing [46] 4. Upcoming Economic Data and Events Economic Data - Various economic data will be released on October 27, including Japan's September corporate service price index, China's September industrial enterprise profits, etc. [48] Events - The central bank has 7000 billion yuan of 1 - year MLF and 189 billion yuan of 7 - day reverse repurchases maturing [50] - The governor of the Reserve Bank of Australia will participate in a talk [50] - There are new stock subscriptions and company earnings reports [50] - Multiple important events are scheduled, such as the East Asia Cooperation Leaders' Series Meetings, the 2025 Financial Street Forum Annual Conference, etc. [50]

Group 1 - The pharmaceutical sector opened high on October 27, with the Hong Kong pharmaceutical ETF (159718.SZ) rising by 1.02% [1] - Notable stocks such as WuXi AppTec (药明康德) reported a revenue of RMB 32.86 billion for the first three quarters of 2025, marking an 18.6% year-on-year increase, and a net profit of RMB 12.076 billion, up 84.84% [1] - WuXi AppTec expects its revenue for the full year to be adjusted from RMB 42.5-43.5 billion to RMB 43.5-44 billion, with a focus on its CRDMO core business [1] Group 2 - The CXO sector continues to show strong performance, with companies like WuXi AppTec, Boteng Co., and MEDPACE exceeding expectations [2] - The innovative drug industry chain fundamentals remain positive, supported by recent financing data and the sustainable trend of innovative drugs going global [2] - The Hong Kong pharmaceutical ETF (159718.SZ) offers a balanced composition, including innovative drugs, CXO, internet healthcare, and innovative medical devices, making it a convenient investment tool for the sector [2]

Core Insights - The Hong Kong Medical ETF (159366) and the CSI Hong Kong Stock Connect Medical Theme Index (932069) have shown strong performance, with the index rising by 2.35% and the ETF by 2.42% on the opening day [1] - WuXi AppTec (药明康德) reported significant growth in its Q3 2025 financial results, with a revenue of 12.057 billion yuan, a year-on-year increase of 15.26%, and a net profit of 3.515 billion yuan, reflecting a 53.27% increase [3] - The strong performance of WuXi AppTec is attributed to its core business growth, particularly in the chemical segment, which saw a revenue increase of 29.3% year-on-year [3] Company Performance - WuXi AppTec's Q3 revenue was 12.057 billion yuan, with a net profit of 3.515 billion yuan, and a non-recurring gain of 3.223 billion yuan from the sale of equity in WuXi XDC Cayman Inc. [3] - The chemical business is the main growth driver, with TIDES (peptides and oligonucleotides) revenue reaching 7.84 billion yuan, a remarkable increase of 121.1% year-on-year [3] - The company's core strategy in CRDMO is yielding high growth, with a 17.1% increase in orders in the TIDES sector [3] Industry Trends - The overseas CXO industry is experiencing a recovery, with an increase in BD transactions and M&A activities, indicating a positive trend in global client demand [4] - Leading CXO companies with a global client base and advanced manufacturing capabilities are expected to benefit from this recovery [5] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index account for 62.95% of the index, highlighting the concentration of investment in key players like WuXi AppTec and JD Health [5]

Financial Data and Key Metrics Changes - The company's total revenue for the first three quarters of 2025 reached RMB 32.86 billion, with revenue from continuing operations growing 22.5% year-over-year to RMB 32.45 billion [6][7] - Adjusted non-IFRS net profit increased by 43.4% to RMB 10.54 billion, with a non-IFRS net profit margin improving to 32.1% [7][20] - The adjusted non-IFRS gross profit reached RMB 15.46 billion, with the gross profit margin improving from 41.6% in 2024 to 47% [19][20] Business Line Data and Key Metrics Changes - WuXi Chemistry's revenue grew 29.3% to RMB 25.98 billion, with an adjusted non-IFRS gross profit margin improving 5.8 percentage points to 51.3% [8][9] - Small molecule D&M business revenue grew 14.1% to RMB 14.24 billion, with a total react volume of small molecule APIs exceeding 4,000 cu m [9][10] - WuXi TIDES revenue surged 121.1% year-over-year to RMB 7.84 billion, with a backlog growth of 17.1% [10][11] Market Data and Key Metrics Changes - Revenue from the U.S. grew 31.9%, while Europe saw a 13.5% increase, and revenue from China remained flat [8] - The company reported a record backlog for continuing operations of RMB 59.88 billion, growing 41.2% year-over-year [7][8] Company Strategy and Development Direction - The company is focusing on enhancing its core CRDMO capabilities and expanding global capacity to meet customer demand [7][25] - A strategic decision was made to sell 100% of its China-based clinical research services business to Hillhouse Investment Management, which will be classified as a discontinued operation [23][24] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth in continuing operations revenue for 2025, raising the growth rate expectation to 17%-18% [25][26] - The company anticipates total revenue for 2025 to be between RMB 43.5 billion and RMB 44.0 billion, up from previous guidance [26] Other Important Information - The company has implemented a total of RMB 6.88 billion in cash dividends, share repurchases, and cancellations, representing over 70% of the net profit in 2024 [27][28] - The company is actively advancing global capacity expansion, with CapEx payments reaching RMB 3.57 billion in the first three quarters [22] Q&A Session Summary Question: What is driving the backlog growth, particularly in small molecules? - Management indicated that the backlog growth is primarily driven by small molecule D&M, especially from late-stage clinical and commercial projects, with a historical high backlog approaching RMB 60 billion [30][32] Question: What is the outlook for margins, especially for WuXi Chemistry? - The margin increase is attributed to continuous optimization of manufacturing processes and a higher proportion of late-phase and commercial projects, with expectations to maintain strong margins moving forward [35][36] Question: How does the new BIOSECURE bill affect customer sentiment? - Management noted that customers have not shown a significant change in demand patterns despite the geopolitical uncertainties, maintaining strong service demand [40][42] Question: What is the expected timing for the disposal of the clinical research services business? - The revenue guidance for continuing operations has excluded the clinical research services business, which will be reclassified as discontinued operations in the annual report [47] Question: What are the key drivers for the small molecule CDMO business? - The small molecule pipeline includes several high-potential projects, including GLP-1 and PCSK9, with a strong focus on capturing late-phase and commercial opportunities [70]

Financial Data and Key Metrics Changes - The company's total revenue for the first three quarters of 2025 reached RMB 32.86 billion, with revenue from continuing operations growing 22.5% year-over-year to RMB 32.45 billion [6][7] - Adjusted non-IFRS net profit increased by 43.4% to RMB 10.54 billion, with a non-IFRS net profit margin improving to 32.1% [7][20] - The adjusted non-IFRS gross profit margin improved from 41.6% in 2024 to 47% in the first three quarters of 2025 [19][20] Business Line Data and Key Metrics Changes - WuXi Chemistry's revenue grew 29.3% to RMB 25.98 billion, with an adjusted non-IFRS gross profit margin improving 5.8 percentage points year-over-year to 51.3% [8][9] - WuXi TIDES revenue surged 121.1% year-over-year to RMB 7.84 billion, with a backlog growth of 17.1% [10] - WuXi Testing revenue remained flat at RMB 4.17 billion, while lab testing service revenue grew 7.2% year-over-year [13][14] - WuXi Biology revenue increased by 6.6% to RMB 1.95 billion, with a slight decline in gross profit margin due to market pricing impacts [17] Market Data and Key Metrics Changes - Revenue from the U.S. grew 31.9%, while Europe saw a 13.5% increase, and revenue from China remained relatively flat [8] - The company's backlog for continuing operations reached a record high of RMB 59.88 billion, growing 41.2% year-over-year [7][32] Company Strategy and Development Direction - The company is focusing on enhancing its core CRDMO capabilities and expanding global capacity to meet customer demand [7][25] - A strategic decision was made to sell 100% of its China-based clinical research services business to Hillhouse Investment Management, which will be classified as a discontinued operation [23][24] - The company expects to achieve double-digit growth in continuing operations revenue for 2025, raising the growth rate guidance to 17% to 18% [25][26] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the robust demand for enabling services and the resilience of the CRDMO business model [25] - The company anticipates improved operating efficiency and financial management capabilities to sustain growth momentum [19][22] Other Important Information - The company has implemented a total of RMB 6.88 billion in cash dividends, share repurchases, and cancellations, representing over 70% of the net profit in 2024 [27][28] - The company is actively advancing global capacity expansion, with CapEx payments reaching RMB 3.57 billion in the first three quarters [22] Q&A Session Summary Question: What is driving the backlog growth, particularly in the small molecule segment? - Management indicated that the backlog growth is primarily driven by late-stage clinical and commercial projects, with a significant contribution from small molecule DNM [30][32] Question: What is the outlook for margins, especially for WuXi Chemistry? - The high margins are attributed to continuous optimization of manufacturing processes and an increase in late-phase and commercial projects, which improve utilization efficiency [35][36] Question: How do U.S. customers view the new BioSecure bill and its impact on sourcing? - Management noted that U.S. customers continue to demand services from global sites, and there has not been a significant change in sourcing patterns due to the new bill [40][42] Question: How will the disposal of the clinical research services business affect overall margins? - The margin mix for WuXi Testing is expected to improve following the divestiture of the clinical CRO business [86] Question: What are the plans for using the proceeds from recent disposals? - The proceeds will be reinvested into global growth and capacity building, supporting the company's CRDMO strategy [86]

Group 1 - The Hong Kong stock market opened higher on October 27, with technology and semiconductor stocks showing strength [1] - The Hong Kong Stock Connect Technology ETF (513860) rose by 1.96% with a trading volume exceeding 30 million yuan, indicating strong investor interest [1] - Notable performers among the ETF's constituent stocks included Hongteng Precision, which increased by over 7%, and WuXi AppTec and WuXi Biologics, both rising by over 6% [1] Group 2 - According to Xinda Securities, the derivatives market is showing positive signals despite a reduction in positions, with the basis of the Shanghai 50 index futures turning to a premium, indicating improved sentiment in blue-chip stocks [2] - Huatai Securities noted that southbound capital has accumulated inflows exceeding 500 billion HKD since the second half of the year, suggesting a balanced risk outlook in the market [2] - The current high prosperity in sectors such as metals, materials, and energy, along with technology, contrasts with the recent bottoming or upward revision signs in consumer sectors and high-dividend stocks [2]

Financial Data and Key Metrics Changes - The company's total revenue for the first three quarters of 2025 reached RMB 32.86 billion, with revenue from continuing operations growing 22.5% year-over-year to RMB 32.45 billion [5] - Adjusted non-IFRS net profit increased by 43.4% to RMB 10.54 billion, with a non-IFRS net profit margin improving to 32.1% [5][17] - The adjusted non-IFRS gross profit margin improved from 41.6% in 2024 to 47% in 2025 [17] Business Line Data and Key Metrics Changes - WuXi Chemistry's revenue grew 29.3% to RMB 25.98 billion, with an adjusted non-IFRS gross profit margin improving 5.8 percentage points year-over-year to 51.3% [6][7] - WuXi TIDES revenue surged 121.1% year-over-year to RMB 7.84 billion, with a backlog growth of 17.1% [8] - WuXi Testing revenue remained flat at RMB 4.17 billion, while lab testing services revenue grew 7.2% year-over-year [11][12] Market Data and Key Metrics Changes - Revenue from the U.S. region grew 31.9%, while Europe saw a 13.5% increase, and revenue from China remained relatively flat [6] - The company's backlog for continuing operations reached a record RMB 59.88 billion, growing 41.2% year-over-year [5][6] Company Strategy and Development Direction - The company plans to focus on its core CRDMO business model and accelerate global expansion, capacity construction, and capability development [21][23] - A strategic decision was made to sell 100% of its China-based clinical research services business to Hillhouse Investment Management, which will be classified as a discontinued operation [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth in continuing operations revenue for 2025, raising the growth rate expectation to 17% to 18% [23][24] - The company anticipates total revenue for 2025 to be between RMB 43.5 billion and RMB 44.0 billion, up from previous guidance [24] Other Important Information - The company has implemented a total of RMB 6.88 billion in cash dividends, share repurchases, and cancellations, representing over 70% of the company's net profit in 2024 [25] - The company is actively advancing global capacity expansion, with CapEx payments reaching RMB 3.57 billion in the first three quarters [19] Q&A Session Summary Question: What has been driving the backlog growth, particularly in the small molecule part? - The backlog growth is mainly driven by contributions from small molecule DNM, especially from late-stage clinical and commercial projects [30] Question: What has been driving the high gross margin in the third quarter? - The high margin is attributed to continuous optimization of the manufacturing process and an increase in late-phase and commercial projects, improving utilization efficiency [34] Question: How do U.S. customers view the new BioSecure bill? - Customers have not shown a significant change in demand patterns, and the company continues to meet service demands effectively [40] Question: Does the raised guidance for the full year include the clinical research services business? - The guidance for continuing operations has excluded the clinical research services business, which will be reclassified as discontinued operations [45] Question: What is the outlook for early-stage demand? - There has been a rise in early-stage demand, particularly from U.S. customers, driven by the company's differentiated capabilities [47] Question: What are the key drivers in the small molecule CDMO business? - The small molecule pipeline includes multiple potential big projects, including GLP-1 and other therapeutic areas [60]

Financial Data and Key Metrics Changes - The company's total revenue reached RMB32.86 billion, with revenue from continuing operations growing 22.5% year over year to RMB32.45 billion [7] - Adjusted non-IFRS net profit increased by 43.4% to RMB10.54 billion, with a net profit margin of 32.1% [7][27] - The backlog for continuing operations reached a record RMB59.88 billion, growing 41.2% year over year [8] Business Line Data and Key Metrics Changes - Chemistry's CRDMO revenue grew 29.3% to RMB25.98 billion, with an adjusted non-IFRS gross profit margin improving by 5.8 percentage points to 51.3% [11] - Small molecule DNM business revenue increased by 14.1% to RMB14.24 billion [13] - WuXi Tides revenue surged 121.1% to RMB7.84 billion, with a backlog growth of 17.1% [14] Market Data and Key Metrics Changes - Revenue from the U.S. region grew 31.9%, while Europe saw a 13.5% increase, and revenue from Japan, Korea, and the rest of the world grew 9.2% [10] - Revenue from China remained relatively flat, indicating a diversified revenue stream [10] Company Strategy and Development Direction - The company is focusing on enhancing core capabilities and expanding capacity to meet customer demand [7] - An agreement was signed to sell 100% of the equity of its China-based clinical research service business, which will be classified as a discontinued operation [32][33] - The company raised its full-year guidance for continuing operations revenue growth to 17% to 18% [37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in customer demand for enabling services and the resilience of the CRDMO business model [36] - The company expects to improve adjusted non-IFRS net profit margins in 2025 and anticipates free cash flow to increase [37][38] Other Important Information - The company has implemented a total of RMB6.88 billion in cash dividends and share repurchases, representing over 70% of net profit in 2024 [38] - The company is actively advancing global capacity expansion, with CapEx payments reaching RMB3.57 billion in the first three quarters [30] Q&A Session Summary Question: What is driving the backlog growth, particularly in small molecules and Tides business? - Management noted that the backlog has reached a historical high, driven by small molecule DNM and Tides business, with a year-over-year growth of approximately 30% [44][45] Question: What is the outlook for margins moving forward? - The company indicated that margin growth is driven by continuous optimization of manufacturing processes and an increase in late-phase and commercial projects [50][51] Question: How do U.S. customers view the new legislative proposals regarding biotechnology? - Management stated that they are closely monitoring legislative changes and have not seen a significant shift in customer demand patterns [54][58] Question: What is the impact of the disposal of the clinical research service business on margins? - The margin mix is expected to improve following the divestiture of the clinical CRO business, enhancing the overall margin of the WuXi testing business [110] Question: How will the company utilize the cash from the recent transactions? - The cash will be used to support global growth and capacity building initiatives [112]

（文章来源：每日经济新闻） 每经AI快讯，药明康德(02359.HK)高开逾7%，截至发稿，涨7.51%，报118.8港元，成交额3129.39万港 元。 ...

Core Viewpoint - The Hong Kong stock market shows signs of volatility in the short term, but the long-term upward trend remains intact, with specific sectors, particularly technology, expected to benefit from AI narratives and structural advantages in asset allocation [1][1][1]. Market Performance - The Hang Seng Index opened up by 1.28%, while the Hang Seng Tech Index rose by 2.06%. Notable stock performances include Alibaba increasing by nearly 4%, Baidu Group and SMIC rising over 3%, and Kuaishou gaining over 2%. WuXi AppTec saw a significant increase of over 7%, with a year-on-year net profit growth of 53.27% in Q3 [1][1][1]. Analyst Insights - Dongwu Securities indicates that while recent events may lead to continued short-term volatility in the Hong Kong market, the long-term upward trend is unchanged [1]. - Guotai Junan suggests that short-term fluctuations do not alter the bullish outlook for the fourth quarter, particularly for the Hang Seng Tech Index, which has the most potential for growth [1][1]. - China Merchants Securities notes a consensus of pessimistic expectations in the Hong Kong market, influenced by anticipated fluctuations due to US-China trade tensions. However, it emphasizes that the long-term upward trend remains, advising a focus on structural themes rather than index points [1][1][1].